Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients ( N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg] or high-dose: 1.25 mg/day [20 to 45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of autism and developmental disorders 2013-08, Vol.43 (8), p.1773-1783
Hauptverfasser:	Kent, Justine M., Kushner, Stuart, Ning, Xiaoping, Karcher, Keith, Ness, Seth, Aman, Michael, Singh, Jaskaran, Hough, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Aberrant Behavior Checklist Adolescent Adolescents Anesthesia Autism Autistic adolescents Autistic children Autistic Disorder - diagnosis Autistic Disorder - drug therapy Behavior Change Behavioral Science and Psychology Biological and medical sciences Check Lists Child Child & adolescent psychiatry Child and School Psychology Child clinical studies Child, Preschool Children Control Groups Developmental disorders Dosage Dosage and administration Double-Blind Method Drug dosages Drug Therapy Dyskinesia Eating behaviour Experimental design Experimental Groups FDA approval Female Humans Infantile autism Male Medical sciences Mental Age Metabolism Neuropharmacology Neurosciences Obsessive Compulsive Scale Original Paper Outcomes of Treatment Pediatrics Pervasive developmental disorders Pharmacology. Drug treatments Placebos Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Public Health Risperidone Risperidone - administration & dosage Risperidone - adverse effects Risperidone - pharmacokinetics Risperidone - pharmacology Serotonin Antagonists - administration & dosage Serotonin Antagonists - adverse effects Serotonin Antagonists - pharmacokinetics Serotonin Antagonists - pharmacology Severity (of Disability) Severity of Illness Index Symptoms (Individual Disorders) Teenagers Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients ( N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg] or high-dose: 1.25 mg/day [20 to 45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(−12.4 [6.5]; p
ISSN:	0162-3257 1573-3432
DOI:	10.1007/s10803-012-1723-5